Momentum Builds for New ADINA Bill to Label Allergens in Drugs

The lobbying family: Seth, Jennifer and Adina Togal.

Adina Togal’s family wants 2026 to be the year that lawmakers pass federal legislation for allergen transparency on drug labels. The Allergen Disclosure in Non-Food Articles (ADINA) Act would require labeling for the top 9 food allergens and gluten on prescription and over-the-counter medications.

Adina and her parents, Seth and Jennifer Togal continue working to garner support for the bill and their efforts are paying off. New co-sponsors have come on board, doubling the number of lawmakers attaching their names to the proposed legislation since November 2025 to 14.

“We’re hopeful that 2026 will show a big push like we saw in 2024, as the second year of the Congressional session,” Seth Togal tells Allergic Living.

Minnesota Rep. Kelly Morrison, the Togals’ local representative, reintroduced the bi-partisan bill in the U.S. House of Representatives on June 6, 2025. The bill HR 3821 would amend the Food Allergen Labeling and Consumer Protection Act (FALCPA). The proposed legislation is co-led by representatives Mike Lawler, Doris Matsui, and Ben Cline.

“Nobody should be in danger of a life-threatening allergy attack simply because they took medication,” Morrison says. “I’m thankful to my constituent Adina and her family for their fight to make our country safer and healthier.”

The Minneapolis family has been advocating for change in medication labels since Adina suffered a reaction to an undisclosed allergen in medication she was given while at a sleep-away camp in 2022. Adina, 14, is allergic to dairy and has celiac disease and eosinophilic esophagitis (EoE), which is triggered by gluten and other foods.

Her parents’ frustration over the inability to obtain clear information about the ingredients in the prescribed antibiotic sparked the start of their legislative journey. The bill inspired by Adina was first introduced in June 2023.

ADINA Bill: Born from a Serious Reaction

Adina has watched as her parents spend countless hours searching in vain for ingredient information on her medications. She’s seen them again and again contact pharmacies and drug manufacturers.

“I know it can be really hard. Doing all the work and not getting any answers,” she told participants during a webinar hosted by the food allergy nonprofit FARE.

At the Wisconsin camp in 2022, Adina developed strep throat that required medicine. When the camp’s nurse contacted her parents about the antibiotic, the Togals immediately attempted to find information about its ingredients.

To avoid delaying treatment, they ultimately gave permission for Adina, then 11, to take the antibiotic. But Adina soon experienced symptoms that included dropping blood pressure, brief loss of consciousness, vomiting and other gastrointestinal symptoms. Then she was rushed to the hospital when her blood pressure dipped dangerously low.

Adina’s parents suspect the medicine contained or had cross-contact with gluten. Although she recovered, their inability to find clear answers fueled their push toward allergen drug labeling.

ADINA Act Advocacy Efforts

Minnesota Rep. Kelly Morrison reintroduced the bill in June 2025.

The Togals are organizing their advocacy efforts to build on support that was gained for the ADINA Act the first time around.

A growing list of Democrat and Republican co-sponsors is evidence of their efforts. They are working to bring on new legislators, as well as regain the support of legislators who co-sponsored during the last session, Seth Togal says. (Co-sponsorships do not carry over from one Congress to the next.)

“Our primary advocacy push continues to be constituent outreach to U.S. Representatives to secure additional co-sponsors for the ADINA Act,” Jennifer Togal says.

In addition, the Togal family wants to collect data to illustrate the consequences of inadequate medication labeling. They plan to launch a formal survey about patient experiences, Adina’s mom says.

“This data is crucial as we are currently stuck in a loop,” Jennifer Togal says.

The hope is that the survey results will help fill in the gaps where data are lacking on reactions caused by food-derived allergens and gluten in medications. Currently, because the medications are not labeled, physicians can’t clearly identify the allergens as a cause of a reaction to report the data, she says.

“Our end goal is to make sure that all top allergens plus gluten-containing grains are labeled in plain language for the consumer,” Jennifer Togal says.

The bill is also endorsed by several advocacy groups. They include FARE, Beyond Celiac, the Food Allergy & Anaphylaxis Connection Team (FAACT), the American Partnership for Eosinophilic Disorders (APFED), Pill Clarity, and Red Sneakers for Oakley.

How to Support the Drug Labeling Bill

The Togals want others to join their advocacy as they stand by their motto, “Quiet persistence is for the win.”

Adina’s parents are urging lawmakers to support the bill, using the knowledge they have gained about the most effective ways to share their message. They also are meeting with clinicians, allergists, leaders in the food allergy and celiac disease communities, schools of pharmacology, and industry stakeholders.

“You have to take action, you have to call, request meetings. Be in their faces, kindly and respectfully,” Seth Togal says.

Constituents can help take action by reaching out to their representative to request a virtual or in-person meeting, or making a phone call to the lawmaker’s office.

“Nearly all congressional offices offer virtual meetings, and they are far more impactful than emails alone,” Jennifer Togal says.

Here are ways to support the ADINA Act and keep up with information about the bill:

Visit the website Adinaact.com. Resources on ways to advocate to your representative for the proposed legislation, along with a sample letter, are available.
Follow The ADINA Act Effort on Instagram.
Call or write your U.S. Representative and urge them to co-sponsor the ADINA Act (H.R. 3821, 119th Congress, 2025–2026). Information about your lawmaker is available at Congress.gov.
Email [email protected] with real-life testimonials. These can include experiences with medication reactions, treatment delays, insurance barriers, or anything related to the challenges caused by not having plain-language allergen and gluten labeling on medication.

Adina’s own story is a big part of her family’s advocacy efforts, and sharing more people’s experiences can help make a difference. “These stories are essential to demonstrating real-world impact,” Jennifer Togal says.